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Insomni og risiko for hjerte- og karsykdom 
Forskning som har blitt utført det siste tiåret har gitt resultater som taler for at dårlig 
søvn og søvnlidelser bidrar til utvikling av hjerte- og karsykdom. Insomni er definert 
som en subjektiv opplevelse av å ha problemer med innsoving, for tidlig oppvåkning 
om morgenen og/eller dårlig søvnkvalitet, og insomni ansees for å være den vanligste 
søvnforstyrrelsen.  Forekomsten av minst ett av symptomene kan være så høy som 33% 
i den generelle befolkningen. Foreløpig er det få studier på sammenhengen mellom 
insomni og risiko for framtidig hjerte- og karsykdom. Insomni henger sammen med en 
ugunstig livsstil og utvikling av metabolsk syndrom, som betyr at personer med insomni 
ofte har høyere blodtrykk, kolesterol og høyere kroppsmasseindeks enn personer uten 
slike søvnplager. En annen mulighet for sammenhengen er at søvnproblemene bidrar til 
økt utskillelse av inflammatoriske stoffer i blodet som kan øke risikoen for hjerte- og 
karsykdom. Om det er en klar sammenheng mellom metabolsk syndrom og 
inflammasjon, er heller ikke kjent, og spesielt er dette uavklart i yngre aldersgrupper.  
Studiene i avhandlingen tok utgangspunkt i den andre Helseundersøkelsen i 
Nord-Trøndelag (HUNT-2) som foregikk i perioden 1995-97. Alle personer over 20 år i 
fylket ble invitert, og deltakerne fylte ut spørreskjema, gjennomgikk en klinisk 
undersøkelse, og det ble tatt blodprøver. I spørreskjemaet ble det blant annet spurt om 
søvnplager. Fra undersøkelsen startet til og med 2008 ble det fortløpende registrert 
førstegangs hjerteinfarkt eller hjertesvikt, hvor opplysningene enten ble hentet fra 
sykehusjournaler i Helse-Nord Trøndelag eller fra Dødsårsaksregisteret.  I en 
undergruppe bestående av 10 000 deltakere ble det målt høy-sensitivt C-reaktivt protein 
(hsCRP) i blod, som er et mål på graden av inflammasjon i kroppen.  
Resultatene viste at personer med symptomer på insomni hadde en moderat økt 
risiko for førstegangs hjerteinfarkt og økt risiko for hjertesvikt sammenliknet med 
personer uten søvnproblemer. Vi fant også at sjansen for å få hjerteinfarkt eller 
hjertesvikt var høyere jo flere symptomer på insomni som var tilstede samtidig. Vi tok 
høyde for betydningen av andre faktorer som kunne påvirke resultatene, og i de 
statistiske analysene justerte vi for forskjeller i alder, kjønn, ekteskapsstatus, 
utdanningsnivå, skiftarbeid, blodtrykk, kolesterol, diabetes, vekt, fysisk aktivitet, 
alkohol og røyking. I tillegg justerte vi for symptomer på depresjon og angst, som begge 
kan medføre søvnplager. De justerte analysene viste at disse mulig konfunderende 
faktorene ikke påvirket resultatene i nevneverdig grad, noe som styrker sannsynligheten 
for at våre funn har en underliggende biologisk årsak. I en annen studie fant vi at den 
positive sammenhengen mellom metabolsk syndrom og hsCRP var like tydelig i alle 
aldersgrupper. Til tross for at personer med insomni oftere har metabolsk syndrom, fant 
vi ingen holdepunkter for at personer med insomni har økt utskillelse av hsCRP. Disse 
funnene taler imot at inflammasjon, indikert av høy hsCRP, kan forklare 
sammenhengen mellom insomni og framtidig hjerte- og karsykdom.  
Til tross for at insomni er forbundet med en moderat risikoøkning for hjerte- og 
karsykdom, er insomni så vanlig i befolkningen at søvnplager kan spille en viktig rolle 
for hjertehelse. I tillegg er insomni en lett gjenkjennbar og potensielt håndterbar 
  
tilstand.  I forebygging av hjerte- og karsykdom bør derfor søvnplager tas med i 
vurderingen. Det kreves mer forskning på området, slik at man får en bedre forståelse av 
de underliggende mekanismene. 
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1    Introduction 
Cardiovascular disease (CVD) is the leading cause of death worldwide. According to 
the estimations of the World Health Organization, more than 17 million people died of 
CVDs in 2008, which accounts for 31% of all deaths.1 Among the most common forms 
of CVD are coronary heart disease (CHD) and heart failure (HF). CHD occurs when the 
supply of blood to the heart muscle cells is hampered due to the narrowing of the 
coronary vessels, while HF is usually defined as the inability of the heart to supply 
sufficient blood flow to meet the needs of the body.  
A large proportion of CVDs is preventable through the reduction of potentially 
modifiable risk factors, including tobacco smoking, overweight, dyslipidemia, 
hypertension, physical inactivity, poor diet, and psychosocial factors.2 Over the last two 
decades, cardiovascular mortality rates have declined substantially in high-income 
countries.3 There is clear evidence that both population-wide primary prevention and 
individual health-care intervention strategies have contributed to the decline in CVD 
mortality.4 However, a large proportion of CHD patients do not have any of the 
established conventional risk factors,5 and because CHD is still by far the leading cause 
of death in the industrialized countries, it is important to learn more about the 
underlying causes and to reveal other potentially preventable risk factors.  
Research over the last decades has provided increasing evidence that poor sleep 
and sleep disorders may contribute to the development of CVD. First, obstructive sleep 
apnea was recognized as a strong risk factor for both acute myocardial infarction (AMI) 
and for cardiovascular disease in general.6,7 Obstructive sleep apnea is a primary sleep 
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disorder that is common in middle age. It is caused by repetitive episodes of airway 
obstruction during sleep that leads to frequent awakenings during the night, loud 
snoring and increased sleepiness during the day. In relation to other sleep problems, 
there is considerable less knowledge about their associations with CVD.  
Among the different sleep disorders, we have concentrated on insomnia in this 
thesis. Insomnia is a subjective feeling of having difficulty initiating or maintaining 
sleep or having a feeling of non-restorative sleep.8 It is a highly prevalent condition in 
the industrialized world and is the most common primary sleep disorder. It has been 
estimated that the prevalence of at least one insomnia symptom could be as high as 33% 
in the general population.9 Little is known about the cardiovascular effects of insomnia. 
Therefore, our main aim was to prospectively investigate the association of insomnia 
with risk for acute myocardial infarction and heart failure in a large population-based 
study. Another aim was to explore possible mechanisms related to insomnia and 
cardiovascular disease, with emphasis on inflammatory and metabolic factors.   
Below, we first outline the atherosclerotic process and its clinical manifestations. 
Then we briefly describe the physiology and pathophysiology of sleep. Finally, we 
summarize the current knowledge related to the association of insomnia and AMI and 
HF, and we attempt to review the possible underlying mechanisms for such an 
association. 
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1.1 Atherosclerosis and cardiovascular disease 
The underlying disease process in the blood vessels that results in cardiovascular 
disease is known as atherosclerosis, which refers to hardening of blood vessels. 
Atherosclerosis typically develops in the arterial wall over a period of decades with 
distinct chronological phases.10,11  
 
1.1.1 The development of atherosclerosis 
Initial phase. The endothelium, the inner lining of blood vessels, is exposed to several 
harmful factors in blood. Such factors include elevated and modified levels of LDL 
(Low Density Lipoprotein), free radicals, as well as microbial pathogens. During the 
initial phase of atherosclerosis the endothelium attempts to repair itself by attracting 
immune cells to the injured site. When the reparative process fails, the endothelium 
becomes permeable and lymphocytes and monocytes migrate into the deep layer of the 
intima where a series of reactions occur attracting LDL particles to the site. These fatty 
LDL particles are engulfed by monocytes, before being transformed into macrophages 
or foam cells. The accumulation of lipid-laden foam cells constitutes the initial 
pathological manifestation of the atherosclerotic process, the so-called fatty streak 
formation. The fatty streaks appear commonly as early as in the first decade of life, but 
at the early stage, the process is still reversible.   
Progressive phase. If the elimination of harmful factors is not complete, the 
inflammatory process continues, and the atherosclerotic lesion develops further. As the 
attempt at endothelial repair progresses, a fibrous cap consisting of smooth muscle and 
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collagen is formed. At the same time, the macrophages and monocytes involved in the 
original reaction are destroyed, which results in the formation of a lipid pool covered by 
the fibrous cap. At this stage the initial fatty streaks transform, with the contribution of 
the immune cells, to an advanced atheromatous lesion or plaque. The progressive phase 
is generally considered to occur during young adulthood through middle age.  
Late phase. While the plaque increases in size, the arterial wall compensates by 
expanding. If the intrinsic compensating capacity of the arteries is exhausted, the 
atheromatous lesion can intrude into the lumen and alter blood flow, and thereby cause 
clinical symptoms. In addition, the atherosclerotic plaque can cause clinical symptoms 
by facilitating thrombosis. The surface of the plaque is in itself thrombogenic and the 
rupture of a plaque may also facilitate thrombosis. Immune activity may facilitate both 
the rupture of the plaque and thrombosis by digestion of the fibrous cap or by changing 
the hemostatic properties of the blood. This latter phase is typically known as 
atherothrombosis, and occurs in middle-aged or elderly individuals.   
It is important to note that the immune system is believed to play a central role at 
all stages of atherosclerosis.12,13 Recently, it has become apparent that atherosclerosis is 
a chronic low-grade inflammatory process affecting large- and medium-sized arteries 
throughout the cardiovascular system.14 A large number of studies have determined that 
several pro-inflammatory biomarkers can give prognostic information about risk of 
CVD beyond that available from traditional risk factors (see 1.1.2).10  Much research 
has focused on high-sensitivity C-reactive protein (hsCRP), which is a biomarker of 
innate immunity. HsCRP is a reliable and relatively cheap biomarker of the underlying 
systemic inflammation, and appears to reflect the activity of atherosclerosis from the 
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early stages that are free of symptoms to the late clinical stages. Increased levels of 
hsCRP have been associated with increased cardiovascular morbidity and mortality in 
population-based cohort studies15-17, and with poor prognosis among survivors of acute 
coronary events.18,19 Therefore, the American Heart Association has suggested that 
hsCRP should have a place in individual risk evaluation related to CHD.20 It is debated, 
however, whether increased levels of C-reactive protein (CRP) should be regarded a 
cause or a consequence of CVD. Some have suggested that CRP is causally linked to 
CVD through pro-inflammatory effects that increase cardiovascular risk by initiating the 
atherosclerotic process.21-23 Another explanation could be reverse causation, since 
cytokines may leak from atherosclerotic plaques into the circulation, with subsequent 
hepatic synthesis of CRP.24 It is also possible that metabolic factors (for example 
obesity) in themselves may cause higher CRP. Interleukin-6 (IL-6) is the primary 
cytokine that is involved in hepatic CRP synthesis, and 30% of the total IL-6 production 
takes place in visceral and subcutaneous fat (Figure 1).25 Thus, CRP may be a bystander 
in the association of various risk factors with CVD. It is also not known whether CRP is 
related to obesity and other cardiovascular risk factors at a young age, when the burden 
of atherosclerotic plaques is low. As we discuss below (see 1.3.5), both metabolic 
factors and inflammation are biologically plausible pathways for adverse effects of 
insomnia. Therefore, one aim of the thesis was to clarify how hsCRP is associated with 
metabolic factors at different ages (Aim 4, see 1.4). 
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Figure1. The secretion of CRP from the liver is induced by the messenger cytokine interleukin-6 (IL-6) produced in 
fatty tissue and in atherosclerotic plaques.   
 
1.1.2 Acute myocardial infarction 
Myocardial ischemia, the main manifestation of CHD, is caused by an imbalance 
between the supply of oxygen and other essential myocardial nutrients and myocardial 
demand for these substances. Myocardial ischemia occurs most commonly as a result of 
obstructive atherosclerosis. AMI is the most important manifestation of atherosclerosis 
and CHD, and it occurs when cardiac myocytes die due to myocardial ischemia. AMI 
can be diagnosed on the basis of an appropriate clinical history of chest pain, 
electrocardiography and elevated biochemical markers.26  
It has been estimated that in Norway, 12,000 to 15,000 myocardial infarctions 
occurs annually, and a total of 5000 deaths (12.5% of all deaths) are due to CHD each 
year.27 There has been a consistent reduction in the number of deaths from CHD in 
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middle age in Norway. The prognosis after an AMI has also improved during the last 
decades, and 90% of hospitalized cases of AMI survive the acute phase.28 However, 
among those who survive there is an increased subsequent risk for heart failure, stroke 
or sudden death.29-31 
Atherosclerosis and AMI have a multifactorial but common origin. Certain 
lifestyle habits promote atherogenic traits in genetically susceptible persons. A number 
of risk factors are known to predispose to the condition (Table 1). Some of these, 
including age, sex, race and family history, cannot be changed, whereas other major risk 
factors, such as serum cholesterol, smoking habits, diabetes and hypertension, can be 
modified.32 
 
Table 1. Causes and risk factors for coronary heart disease 
Non-modifiable Modifiable  
Age Hyperlipidemia 
Male sex Cigarette smoking 
Positive family history Hypertension 
Genetic factors Diabetes mellitus 
 Physical inactivity 
 Obesity 
 Poor diet 
 
  Age. CHD rates increase with age. Atherosclerosis is rare in childhood, except in 
familiar hyperlipidemia, but is often detectable in young men between 20 and 30 years 
of age.33-35 The condition is almost universal among the elderly in western societies.36  
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Sex. Men have considerably higher incidence of CHD than women, especially 
before women’s menopause.37 The reason for this sex difference is not clearly 
understood, but it is probably related to hormonal factors and to lifestyle differences.38 
Family history and genetic factors. CHD is often found in several members of 
the same family, and family history is important for CHD risk.39 Most common forms 
of CHD are believed to be a result of several genes acting in combination with 
environmental factors.40 
Cigarette smoking. There is a strong association of cigarette smoking with the 
risk of developing CHD, both related to the number of cigarettes per day, and the 
duration of smoking during the lifetime.41 There is a large body of evidence showing the 
beneficial effect of smoking cessation on CHD mortality.4 It has been shown that those 
who quit smoking between 35 and 44 years of age have the same life expectancy as 
those who have never smoked.42 
Hyperlipidemia. High serum cholesterol, especially when associated with a low 
high-density lipoprotein (HDL), is strongly associated with CHD risk.1,43,44 HDL is the 
fraction of cholesterol that removes cholesterol from the blood vessels. High serum 
triglyceride is also linked with CHD.45 Serum cholesterol levels can be reduced by 
drugs, physical activity and by dietary changes, in particular by a reduction in the 
consumption of saturated fat.2  
Hypertension. Both systolic and diastolic hypertension are associated with an 
increased risk of CHD.4,46  
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Diabetes mellitus is strongly associated with AMI risk. Early detection and 
treatment with strict control of blood glucose is vital for prevention of CHD.4,47  
Poor diet. A diet that is high in saturated fat is associated with increased risk of 
CHD, and similar associations have been shown for low intake of fruit, vegetables and 
fish.48-51 There is evidence from clinical trials that modification of the diet may have a 
significant beneficial impact on the risk of CVD in both primary and secondary 
prevention settings.52  
Obesity. People who are overweight or obese are at increased risk of AMI.53 The 
adverse effect is more pronounced when the fat is concentrated in the abdomen. This is 
known as central obesity and can be identified by a high waist to hip ratio.  
Physical inactivity. A sedentary lifestyle with lack of exercise is an important 
and modifiable risk factor for CHD. It is recommended that adults participate in a 
minimum of 150 minutes of moderate intensity activity every week and in muscle-
strengthening activities on at least two days a week.54 
 
1.1.3 Heart failure 
Heart failure is a complex syndrome that can result from any structural or functional 
cardiac disorder that impairs the ability of the heart to function as a pump to support the 
circulation. The clinical syndrome manifests itself when cellular respiration is impaired 
due to the failure of the heart to pump enough blood to support the metabolic demands 
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of the body, or when normal cellular respiration can only be maintained with an 
elevated left ventricular filling pressure.55  
The prevalence of heart failure is approximately 2% in Norway (i.e. 80,000 to 
100,000 persons) and the incidence increases with age.56 About 75% of heart failure 
cases occur after 75 years of age.57 The clinical syndrome is one of the most frequent 
causes of hospitalizations in the elderly, and it is the main problem among 20% of 
patients admitted to departments of general internal medicine.58 The prognosis of heart 
failure has improved over the past 10 years, but the mortality rate is still high, and only 
about 50% of the patients are expected to be alive after 5 years.59 
Heart failure is diagnosed on the basis of its symptoms and signs as well as 
objective evidence of cardiac dysfunction at rest.55 Typical symptoms of heart failure 
include difficulties breathing, coughing, frequent need to urinate at night and 
generalized fatigue. Common signs are increased rate of breathing, crackles in the lung 
bases and a galloping heart-rhythm. A physical examination can also reveal peripheral 
and central edema. The most frequently used diagnostic tests of heart failure include 
echocardiography, chest radiography and electrocardiography. 
Coronary artery disease is the most frequent cause of heart failure in western 
countries.57  Following an initial myocardial infarction; there is a three- to six fold 
increase in the risk of heart failure.29,60 However, more than 60% of heart failure cases 
are due to other causes than CHD (Table 2).61 
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Table 2. Causes and risk factors of heart failure 
Ischaemic (35-40 %) Non-Ischaemic (60-65 %) 
The same causes as in table 1. Hypertension 
 Valvular heart disease 
 Cardiomyopathies 
 -Familial 
 -Toxic (alcohol, chemotherapy, cocaine) 
 -Infectious (viral, bacterial, fungus, Chagas disease) 
 -Autoimmune (hypersensitivity, connective tissue disorders) 
 -Metabolic (diabetes, overweight, hypo -and hyperthyroidism) 
 -Nutrition (thiamin-, carnitine-, selen deficiency)  
 -Hematologic (haemochromatosis, thalassemia) 
 Atrial fibrillation and other untreated arrhythmias 
 Congenital heart disease  
 Pulmonary causes 
 Myocarditis (viral, bacterial, autoimmune) 
 Pericardial diseases 
 Endocarditis 
 Anaemia 
 Increased heart rate and decreased heart rate variability  
 Increased activity in the sympathetic nervous system 
 Unknown 
 
 
1.2 Normal sleep, circadian rhythm and cardiovascular physiology 
Sleep is a natural process that is crucial for the maintenance and restoration of 
homeostasis. Sleep, like many other aspects of mammalian behavior and physiology, 
including physical activity, alertness, hormone levels, body temperature, immune 
function, and digestive activity, shows circadian rhythmicity. The circadian rhythms are 
controlled by a single tiny brain area, the suprachiasmaticus nucleus (SCN).62 
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Physiological sleep can be divided into non-rapid eye movement (NREM) and 
rapid eye movement (REM) stages. These stages appear in a cyclical manner during 
sleep, with 4 to 5 NREM/REM cycles occurring every night. As sleep progresses, each 
recurring REM episode gets gradually longer. REM sleep is characterized by vivid 
dreams, loss of muscle tone, and rapid eye movement.63 NREM is a deeper stage of 
sleep with the body being least metabolically active.64  
Sleep is an important modulator of cardiovascular function, as sleep may exert 
effects on the autonomic nervous system, cardiac function, systemic hemodynamics, 
endothelial function, coagulation, metabolism and the immune system.  
 
1.2.1 Effects on the autonomic nervous system and hemodynamics 
Cardiac contractility, cardiac output and peripheral vascular resistance are all under 
autonomic nervous control. The autonomic nervous system is affected by the rhythmic 
patterns in homeostatic regulatory mechanisms initiated by SCN. Sympathetic activity 
is higher during the day, while parasympathetic activity is more pronounced at night.65 
As a result, there is also cyclical variation in cardiovascular hemodynamics over a 24 
hours cycle, with the lowest heart rate and blood pressure observed during the night, 
followed by an early morning increase in heart rate and blood pressure. In association 
with specific sleep phases, NREM is characterized by a progressive decrease in 
sympathetic activity with an accompanying parasympathetic predominance, which leads 
to decreases in heart rate, cardiac output, peripheral vascular resistance, and blood 
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pressure. Contrary to this, REM sleep is accompanied by sympathetic activity leading to 
elevated blood pressure and heart rate, similar to levels during wakefulness.66  
 
1.2.2 Effects on endothelial function and coagulation 
Brachial artery flow-mediated endothelium-dependent vasodilatation is decreased and 
coronary artery vascular tone is markedly increased in the early morning after 
awakening compared with that during sleep, and subsequently recovers by late 
morning.67,68 Similarly, increased platelet aggregation, blood viscosity and 
coagulability, increased secretion of tissue plasminogen activator, and fibrinolytic 
activity have been measured in early morning.69,70 These changes are mainly caused by 
increased activity in the sympathetic nervous system.71,72 
 
1.2.3 Effects on metabolism 
It is believed that during normal sleep the metabolic rate is reduced by around 15% and 
reaches a minimum in the morning in a standard circadian pattern.73 When we are 
awake our brain cells use a considerable amount of glucose and the intracellular 
glycogen stores become depleted during the day. During sleep this process is reversed 
so that glucose is available during the next period of wakefulness. It has been shown 
that glucose utilization in normal subjects is at its highest during the wakeful state and 
lowest in NREM sleep and intermediate in REM sleep.74 During the NREM sleep, 
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energy is conserved and body temperature drops. These metabolic changes seem to be 
controlled by reproducible changes in the release of growth hormone and cortisol.75 
Sleep-wake behavior has also been linked with neurohormonal regulation of 
appetite. Ghrelin and leptin are two hormones that regulate energy balance in a 
reciprocal fashion.76 Leptin is an adipocyte hormone that signals satiety to the brain and 
increases energy expenditure. Ghrelin is produced mainly in the stomach and it signals 
hunger to the brain. The interplay of these two hormones is important for regulation of 
sleep. In essence, leptin down-regulates NREM sleep and total sleep time, while ghrelin 
promotes NREM sleep.77  
 
1.2.4 Effects on the immune system 
Sleep is also a restorative process that is important for immune system functioning. 
Evidence from research in animals and humans suggests a bidirectional communication 
between the immune and the neuroendocrine system.78 Cytokines may represent the link 
between these systems, and these immunologically active peptides influence the sleep-
waking cycle of the brain and different stages of sleep, either by promoting or inhibiting 
sleep. However, the exact mechanisms of cytokine-induced signaling of the brain are 
not well understood. 
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1.3 Disturbed sleep and its cardiovascular effects 
During the 20th century many changes in lifestyle have taken place, which influence 
both the length of sleep and sleep quality. Today we have longer work days and an 
increasing number of people are working in shifts. Use of television, personal 
computers, internet and artificial lights curtail our sleep and extend our active phase. 
Sleep deprivation is becoming increasingly common. It has been suggested that the 
average sleep duration has decreased from about 9 hours per night to about 7.5 hours 
during the 20th century.79  
Self-reported short sleep duration and sleep complaints have been associated 
with increased cardiovascular morbidity and mortality in epidemiological studies.80 
Short sleep duration has also been associated with hypertension,81 obesity,82 and 
increased risk of developing diabetes mellitus.83,84  However, the exact mechanisms 
underlying the link between short sleep duration and increased cardiovascular risk are 
largely unknown. Short-term experimental studies on sleep deprivation have tried to 
reveal possible pathophysiological mechanisms behind these associations.  
 
1.3.1 Short-term, experimental sleep deprivation 
Several studies have found that experimental sleep deprivation leads to increased blood 
pressure, which has been related to increased activity in the sympathetic nervous system 
and decreased parasympathetic activation.85-87 Similar physiological changes in the 
autonomic nervous system and hemodynamics are seen during stress and increased 
work expenditure. It has also been proposed that the increased activity in the 
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sympathetic nervous system leads to decreased endothelial function and increased 
coagulability.88,89 
Sleep restriction also induces metabolic dysregulation, as release of anabolic 
hormones involved in the metabolism is altered by sleep restriction.64,77,90 During sleep 
deprivation, the sleep-associated growth hormone pulse at the onset of sleep is 
substantially decreased,91 while cortisol levels are elevated during the evening.79 The 
combined effect of these hormonal changes is slowed glucose metabolism. Sleep 
deprivation also down-regulates the satiety hormone, leptin, and up-regulates the 
appetite-stimulating hormone, ghrelin, which leads to increased hunger and appetite.92 
The combination of slowed glucose metabolism and increased appetite may lead to 
insulin resistance and weight gain.93 
Less is known about the effects of sleep loss on immune function, but acute 
sleep deprivation seems to facilitate the diurnal production of pro-inflammatory 
cytokines IL-6, tumor necrosis factor-α (TNF-α) and CRP.94-99  Studies suggest that 
these cytokines may be important in sleep regulation and for the sleep architecture, and 
play an important role in causing daytime sleepiness and fatigue of sleep-deprived 
individuals.78,100 As described in 1.1.1, the sustained elevation of these pro-
inflammatory cytokines is also a good predictor of cardiovascular morbidity and 
mortality.  
The available experimental data suggest that with short-term sleep deprivation, 
blood pressure, autonomic tone, hormones, metabolism, inflammation and coagulability 
are all altered in a direction that potentially facilitates atherosclerosis. However, the 
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changes seen in experimental settings of acute sleep deprivation are mild and resolve 
quickly with recovery of sleep. There is much less knowledge about whether chronic 
sleep problems and habitual insomnia symptoms lead to the same pathophysiological 
changes. 
 
1.3.2 Insomnia 
1.3.2.1 Definition and Prevalence 
Insomnia is defined as a subjective feeling of having difficulty initiating or maintaining 
sleep or having a feeling of non-restorative sleep.8 Insomnia is not synonymous with 
short sleep or sleep restriction, as it also covers the quality of sleep and not only its 
duration. People with insomnia symptoms could have normal or long sleep duration.101 
Most adults have experienced insomnia or sleeplessness at one time or another 
in their lives and it has been estimated that the prevalence of at least one insomnia 
symptom could be as high as 33% in the general population.9  Insomnia is considered to 
be the most common sleep disorder. It is especially a highly prevalent condition in the 
industrialized world, and about 10% of the general population present chronic insomnia 
complaints and seek medical help for insomnia.102 However, insomnia is an under-
recognized and therefore under-treated problem, since about 60% of people suffering 
from insomnia never talk to their physicians about their difficulties related to sleep.103 
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1.3.2.2 Sociodemographic correlates of insomnia 
Insomnia has several sociodemographic correlates.  
Age. Insomnia affects all age groups. Between 15 and 44 years of age the 
prevalence is stable around 20 %, but it increases from 45 years of age. In elderly 
individuals above 65 years the prevalence is close to 50 %.104 It has been suggested that 
chronic age-related disorders may explain some of the association of age with 
insomnia.105 
Sex. Insomnia affects women more often than men, and the difference increases 
with age.106  
Socio-economic status. Insomnia is more frequent among persons who are 
separated, divorced or widowed, and among people with low educational level and/or 
low economic status, and among people who are unemployed.9 
 
1.3.2.3 Comorbid conditions 
Numerous chronic medical conditions can initiate or maintain insomnia symptoms. 
Nearly 50% of people suffering from insomnia have recurrent or persistent health 
problems.107  
 Medical disorders with chronic pain, like arthritis or back pain; cardiovascular 
diseases, especially heart failure; obstructive respiratory diseases; gastrointestinal 
disorders; chronic renal insufficiency; endocrine conditions, especially thyroid 
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dysfunction, and certain neurological disorders are known to be associated with chronic 
insomnia.108  
Psychological distress. There is also considerable overlap between insomnia and 
psychological distress, especially depressive and anxiety symptoms.109 In persons with a 
current major depressive episode, the presence of insomnia symptoms was found in 
nearly 80% of the patients, and the prevalence was nearly 90% when an anxiety 
disorder was concomitantly present.110  
Substance use. Use, abuse or withdrawal of psycho-active substances is also an 
important cause of insomnia symptoms. Use of drugs, such as beta-blockers, some 
serotonin re-uptake inhibitors, some neuroleptics and amphetamines may result in 
insomnia.9 Withdrawal of hypnotics and anxiolytics may cause rebound insomnia.111 
Alcohol is a central nervous system depressant known for its important effects 
on sleep and wakefulness. Chronic alcoholism is strongly associated with insomnia.112 
Alcohol is also often used as a sleeping aid in the general population, although alcohol 
in the long-term is associated with sleep disruption and creates a sense of non-refreshed 
sleep in the morning.113 Smoking and caffeine has also been found to be positively 
associated with insomnia symptoms.114,115  
 
1.3.2.4 Treatment of insomnia 
It is important to find any comorbid causes of insomnia, as treatment of the underlying 
cause can in itself treat insomnia.116 If no specific cause is identified or elimination of 
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the cause is not possible, there are several treatment options available that may result in 
reliable and durable changes among persons who suffer from chronic insomnia (see 
Table 3).116-118 The combination of pharmacological and non-pharmacological 
interventions provides the optimal treatment.119  
 
Table 3. Treatment options for insomnia 
Non-pharmacological therapies 
Adherence to sleep hygiene rules 
Curtail time in bed 
Avoid the use of clock in the bedroom 
Exercise in the late afternoon or early evening 
Avoid coffee, alcohol, and nicotine 
Regularize the bedtime 
Eat a light bedtime snack 
Avoid daytime napping 
Monitor use of hypnotics 
Progressive muscle relaxation 
Stimulus control 
Helps to re-associate the bed and bedroom with the 
rapid onset of sleep. 
Sleep restriction 
Its objective is to reduce time in bed to lower the chance 
of fragmented and poor-quality sleep. 
Pharmacological therapies 
Benzodiazepines 
Antidepressants 
Melatonine 
 
 1.3.3 Insomnia and coronary heart disease 
Only a few prospective studies have investigated insomnia in relation to risk for CHD, 
and the results have been inconsistent.120-131 Previous studies were small with numbers 
ranging from 416 to 10,308 participants. Only one of these previous studies assessed the 
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three aspects of insomnia simultaneously.124 Most studies concentrated on difficulty in 
initiating and/or maintaining sleep, and generally found a moderately increased risk for 
CHD associated with these symptoms.  
In many studies the outcomes were poorly defined and often based on self-
report. Only a few studies included AMIs that were verified by modern standards, 
including diagnostic information based on electrocardiography and cardiac 
enzymes.122,128,129 The authors combined verified AMI with other less well-defined 
cardiovascular outcomes, and no separate estimates for the verified AMIs were 
reported. In other studies, outcomes were cardiovascular death and/or self-reported 
cardiovascular disease.120,124,125,127  
There is considerable overlap between insomnia and psychological distress, 
especially depressive symptoms.109 There is also some evidence that depression and 
anxiety are associated with increased risk for AMI.132 However, in prospective studies 
of insomnia and AMI, only a few have evaluated and adjusted for depressive symptoms 
in the analyses.121,122,124  
Many common chronic somatic disorders cause sleep problems and are also 
related to AMI. Only a relatively small study attempted to address the possibility that 
chronic disorders could explain the insomnia-AMI association.121  
One of the aims of this thesis (Aim 1, see 1.4) was to investigate prospectively 
the association of insomnia symptoms with the risk of acute myocardial infarction in a 
large population-based study, taking into the account the effects of established 
cardiovascular risk factors, psychological distress, and chronic somatic disorders. 
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1.3.4 Insomnia and heart failure 
Insomnia symptoms are highly prevalent among HF patients. Recent studies indicate 
that the prevalence of these symptoms among HF patients ranges from 23% to 73%.133-
135 However, it is largely unknown whether insomnia is associated with later risk of HF 
among individuals who were free from heart failure at baseline. There is a lack of large 
prospective studies of insomnia and risk of HF, and therefore, another aim of this thesis 
was to investigate the association of insomnia symptoms with the risk of subsequent HF 
in a large population based study (Aim 2, see 1.4). 
 
1.3.5 Possible pathophysiological mechanisms linking insomnia to CVD 
The pathophysiology of insomnia and its link to CVD are not fully understood. 
Insomnia is considered to be a disorder of hyperarousal experienced throughout the 
entire day.136 This hyperarousal may exhibit itself as a state of hypervigilance during the 
day and difficulty initiating and maintaining sleep at night. The hyperarousal in persons 
suffering from insomnia is accompanied by chronic activation of stress responses with 
increased activity in the hypothalamic-pituitary-adrenal axis (HPA axis) and 
sympathetic nervous system.136,137 Cortisol-releasing hormone and cortisol, products of 
the hypothalamus and the adrenals, respectively, are known to cause arousal and 
sleeplessness to humans and animals.102 This stress response is also accompanied by 
increased metabolic rate, increased heart rate, decreased heart rate variability and 
increased blood pressure, secretion of catecholamines and pro-inflammatory 
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cytokines.102,138,139 Thus, abnormalities in the autonomic nervous system and 
neuroendocrine system may represent a biologically plausible causal link between 
insomnia and CVD.  
Insomnia has also been associated with an unhealthy lifestyle, and insomnia is 
associated with an increased prevalence of obesity, physical inactivity and cigarette 
smoking.140 Consequently, insomniacs are more likely to have hypertension, 
unfavorable lipid levels and impaired fasting glucose compared to persons without 
insomnia symptoms.141,142  
Insomnia symptoms also seem to promote unfavorable metabolic changes. The 
increased sympathetic activation and hypercortisolemia in persons with insomnia have 
been implicated in the pathophysiology of insulin resistance and the metabolic 
syndrome. The metabolic syndrome is closely linked to insulin resistance and comprises 
a clustering of various metabolic abnormalities in a given individual that increase the 
risk of diabetes mellitus, cardiovascular disease and premature death.143-146 These 
include the presence of central obesity, an adverse lipid profile (high triglycerides and 
low HDL cholesterol), raised blood pressure and glucose intolerance.147 In a recent 
study, difficulties initiating sleep and non-restorative sleep were associated with 
increased risk of developing metabolic syndrome over a 3-year period.148 Several 
prospective population-based studies have reported that both difficulties initiating sleep 
and maintaining sleep are associated with increased risk of developing type 2 diabetes 
and hypertension.149-151  
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1.3.5.1 Insomnia in relation to inflammation 
Only a few studies have examined chronic sleep problems or habitual insomnia 
symptoms in relation to inflammation, and the results have been inconsistent.152-155 
Most studies were small and few had information on established cardiovascular risk 
factors and other important covariates, including psychological distress or common 
chronic disorders that are known to be associated with both inflammation and insomnia.  
One of the aims of this thesis was to evaluate the associations of insomnia 
symptoms and inflammation measured as hsCRP in a large population (see Aim 3, 1.4).  
               
1.4 Objective 
The aim of this thesis is to contribute to a better understanding of the complex web of 
causes that links insomnia to cardiovascular disease (see figure 2). Therefore, our main 
objective was to investigate prospectively the association of insomnia and risk of acute 
myocardial infarction and heart failure in a large population-based study (Aims 1 and 
2). We also wanted to explore possible mechanisms for such an association, mainly the 
role of inflammation (Aim 3). As a consequence, we investigated the association of 
insomnia with hsCRP in a subset of the population. It is largely established that 
insomnia is associated with an unhealthy lifestyle and with the metabolic syndrome. 
However, as mentioned earlier (section 1.1.1), the association of hsCRP and metabolic 
factors is not clear from the literature, and to shed light on the complex relations 
between insomnia, metabolic factors and inflammation, we also investigated this 
question (Aim 4). 
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In summary, our aims were to examine 
Aim 1 - the association of insomnia with risk of acute myocardial infarction 
Aim 2 - the association of insomnia with risk of heart failure 
Aim 3 - the association of insomnia with hsCRP 
Aim 4 - the association of metabolic factors with hsCRP  
 
 
Figure 2. Possible relations between insomnia, metabolic syndrome, inflammation and cardiovascular disease. 
White arrows refer to associations proposed and investigated in this thesis. Black arrows indicate established 
associations or associations not examined in this thesis.
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2 Methods 
2.1 The Nord-Trøndelag Health Study (HUNT) 
Nord-Trøndelag is one of 19 Norwegian counties and is located in the central part of 
Norway. The county is divided into 24 administrative areas, i.e. municipalities (Figure 
3). Nord-Trøndelag County is considered to be fairly representative of Norway 
regarding geography, economy, and industry, sources of income, age distribution, 
morbidity and mortality.156 The population is stable at about 131,000 inhabitants (2010), 
with a net migration out of the county of 0.3% per year (1996-2000). It is also a 
homogenous population, as less than 3% of the population is non-Caucasian. The 
population is served by two local hospitals, in Levanger and in Namsos.  
The adult population of the county was the study base for the three phases of the 
Nord-Trøndelag Health Study (HUNT). This thesis analyzed data from the second 
phase (HUNT 2).  
All inhabitants in Nord-Trøndelag aged 20 years or older were invited to 
participate in HUNT 2. In total, 94,187 individuals were eligible to participate, and 
65,215 (69%) attended.  
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Figure 3. Norway and Nord-Trøndelag County. Adapted from Holmen et al, Norwegian Journal 
of Epidemiology 2003.156 
 
A questionnaire (questionnaire 1) was attached to the invitation letter. This 
questionnaire was to be completed prior to the clinical examination. A second 
questionnaire (questionnaire 2) was handled out at the clinical examination (see below) 
and was to be completed and returned by mail in a pre-stamped envelope.  
The HUNT study is a collaboration between the HUNT Research Centre, The 
Faculty of Medicine, the Norwegian University of Science and Technology, the 
Norwegian Institute of Public Health, Nord-Trøndelag County Council, and the Central 
Norwegian Regional Health Authority. The Norwegian Board of Health, the Regional 
Committee for Ethics in Medical Research, and the Norwegian Data Inspectorate 
35 
 
approved this study. Participation in HUNT was voluntary, and each participant signed 
a written consent regarding the survey and subsequent follow-up, and to the use of data 
for research purposes.  
A more comprehensive description of the second HUNT study is published 
elsewhere.156  
 
2.2 Study variables 
Information on cardiovascular diseases as endpoints came from the medical records 
from the two hospitals in the county and from the National Cause of Death Registry. All 
other information came from HUNT 2.  
 
2.2.1 Definition and ascertainment of CVD (papers I and II) 
After participating at the baseline examination in HUNT, the participants were followed 
up for a first AMI and incident HF failure from baseline examination until December 
31th, 2008, either identified at hospitals or by the National Cause of Death Registry.  
Hospitalizations for AMI and HF were identified through linkage with medical 
records from the two hospitals of Nord-Trøndelag. AMI and HF were defined and 
diagnosed according to the European Society of Cardiology/American College of 
Cardiology consensus guideline. Criteria for AMI included (1) certain symptoms 
according to case history information, (2) specified changes in the blood levels of 
cardiac enzymes, and (3) specified ECG changes.26 Criteria for HF included symptoms 
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and signs of HF. On the majority of patients echocardiography, radiological 
examinations and biochemical measurements were done.157 The overall quality of the 
hospital diagnoses of AMI and HF in Nordic countries is high.158,159 As there is no 
unequivocal definition of HF, the HF diagnosis in Nordic registers appears slightly less 
precise than for acute myocardial infarction. Accordingly, for the purpose of 
population-based research, only those with a primary diagnosis of HF in the hospital 
discharge register should be regarded as definite cases. Consequently, we included only 
those with a primary diagnosis of HF in the hospital discharge register as definite cases.  
Deaths due to AMI or HF were identified by the National Cause of Death 
registry. Reporting of deaths by physicians and public health officers to the national 
Cause of Death Registry in Norway is mandatory. The data are collected and organized 
by Statistics Norway. The classification is based on International Classification of 
Diseases (ICD) codes. Both the primary and secondary causes of death are reported. 
The unique 11-digit identification number of every Norwegian citizen enables linkage 
of data from the Cause of Death Registry with other data, such as data from the HUNT 
study and the local hospitals in the county. For the analyses, the information on causes 
of death was complete through December 31th, 2008. Deaths from CVD were defined as 
AMI (ICD 9th Revision code 410; ICD 10th Revision codes I21 and I22) and HF (ICD-9: 
428; ICD-10: I50.0, I50.1 and I50.9) as one of the causes of death, respectively.  
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2.2.2 Questionnaires  
Insomnia (papers I-III). The second HUNT questionnaire included 3 items related to 
insomnia. One question was related to difficulty in initiating sleep (“Have you had 
difficulties falling asleep in the last month?” with the following response options: 
never/occasionally/often/almost every night). The second question was related to 
difficulty in maintaining sleep (“During the last month, have you woken up too early 
and not been able to get back to sleep?” with the following response options: 
never/occasionally/often/almost every night). The third question was related to having a 
feeling of non-restorative sleep (“How often do you suffer from poor sleep?” with the 
following response options: never or a few times a year/1-2 times per month/about once 
a week/more than once a week). The last question was restricted to individuals 20 to 69 
years of age. Apart from insomnia symptoms, participants 20 to 69 years of age were 
also asked whether symptoms related to sleep influenced their work situation (“During 
the last year, have you been troubled by insomnia to such a degree that it influenced 
your work performance?” with the response options “yes” or “no”). 
Alcohol intake. The participants were asked about their usual intake of wine, 
beer, and spirits. In papers I-III, we categorized participants according to their alcohol 
consumption indicated by their usual number of drinks over a 2-week period as 
abstainers, light drinkers (0-1 drinks per day), moderate drinkers (>1 but ≤ 2 drinks per 
day), or heavy drinkers (≥ 2 drinks per day). In paper IV, the alcohol intake was 
categorized as less than one drink a month versus one or more drinks per month.  
Level of physical activity. The participants were also asked about their level of 
physical activity. Light physical activity was defined as activity that does not involve 
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sweating or a feeling of breathlessness. In paper I-III, the participants were classified as 
(1) inactive if they reported less than 1 hour of hard and less than 3 hours of light 
activity per week, (2) moderately active if they reported 1 to 3 hours of hard or > 3 
hours of light activity per week, and (3) physically active if they reported ≥ 3 hours of 
hard activity per week.  
Smoking. Responses to questions related to smoking were categorized as current, 
previous or never smoking in papers I-III. In paper IV, smoking was categorized as 
current vs. no smoking.  
Education. In papers I-II, education was categorized as low (≤ 9 years), medium 
(between 10 and 12 years), or high (≥ 12 years). In paper III, education was categorized 
as (1) primary school, 7-10 years (2) high school or intermediate school (3) university 
qualifying examination or junior college (4) university or other post-secondary 
education, less than 4 years (5) university/college, more than 4 years.  
Marital status was dichotomized as living alone or not (papers I-III).  
Shift work. Participants between 20-69 years of age were asked whether they 
worked in shifts (papers I-III).  
Sleep medication/sedatives (papers I-III). In questionnaire 2, participants were 
asked about their use of sleep medication/sedatives (“How often have you taken 
tranquilizers/sedatives or sleep medication in the last month?” with the following 
response options: daily/every week but not every day/less than once a week/never).  
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Common chronic disorders (papers I-III). Participants extensively assessed and 
reported their medical history regarding common chronic disorders, such as previous 
AMI, stroke, asthma, angina pectoris, diabetes mellitus, goiter, hypothyroidism, 
hyperthyroidism, fibromyalgia, arthritis, rheumatism, ankylosing spondylitis, cancer, 
epilepsy, or osteoporosis.  
Hormonal status among women was assessed in questionnaire 2. Female 
participants were asked whether they used hormone replacement therapy or oral 
contraception. They were also asked about menopausal status and ongoing pregnancy. 
In paper III, hormonal status among women was categorized into 4 categories: 
premenopausal not using oral contraception; premenopausal using oral contraception; 
menopausal not using hormone therapy; or menopausal using hormone therapy.  
Depression and anxiety (paper I-III). The Hospital Anxiety and Depression 
Scale was used to assess symptoms of anxiety and depression. A 14 four-point Likert-
scaled item was included in questionnaire 1, 7 for anxiety and 7 for depression. Scores 
on both the anxiety and depression subscales ranged from 0 to 21, and increasing score 
indicated increased symptom load. No somatic items or items regarding sleeping 
difficulties were included. The Hospital Anxiety and Depression Scale has been found 
to have good testing properties in the assessment of symptom severity of anxiety and 
depression both in primary health care and in hospital settings.160 The psychometric 
properties have been validated previously in HUNT 2.161 
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2.2.3 Clinical examination 
The clinical examination was conducted by trained nurses and included standardized 
assessment of blood pressure, weight, height, and waist and hip circumference. Systolic 
and diastolic blood pressures were measured with a Dinamap 845XT (Criticon/GE 
Healthcare) sphygmomanometer based on oscillometry, and the average of the second 
and third measurements was used in the analysis. Height and weight were recorded with 
participants wearing light clothes without shoes; height was measured to the nearest 
centimeter and weight to the nearest 0.5 kilogram. Waist circumference was measured 
to the nearest centimeter at the level of umbilicus. Body mass index (BMI) was 
computed as weight (in kilograms) divided by the squared value of height (in meters). 
 
2.2.4 Laboratory measurements 
A non-fasting serum sample was drawn from each participant at the clinical 
examination, and analyzed at the Central Laboratory, Levanger Hospital, Nord-
Trøndelag, with a Hitachi 911 Autoanalyzer (Mito, Japan). Time between the last meal 
and the venipuncture was recorded, and the samples were sent to the laboratory on the 
same day (some samples drawn on Friday were sent the following Monday).  
Serum concentrations of total serum cholesterol, HDL cholesterol and 
triglycerides (papers I-IV) were analyzed in all participants, applying reagents from 
Boehringer Mannheim. The day-to-day coefficients of variation were 1.3% to 1.9%, 
2.4%, and 0.7% to 1.3%, respectively. Total and HDL cholesterol were measured by an 
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enzymatic colorimetric cholesterol esterase method, and HDL was measured after 
precipitation with phosphotungsten and magnesium ions. Triglycerides were measured 
with an enzymatic colorimetric method.  
In paper IV, we also calculated non-HDL cholesterol as the difference between 
total serum cholesterol and HDL cholesterol and used it as a measure of the lipid 
content of atherogenic lipoproteins.  
All participants from four of 24 municipalities in Nord-Trøndelag County were 
selected for high-sensitivity C-reactive protein measurement (papers III and IV), 
including 9,995 persons. HsCRP was analyzed using an ultrasensitive assay with 
particle-enhanced immunological agglutination. The degree of particle agglutination 
was measured turbidimetrically and the quantification range was 0.1- 20 mg/l. The 
detection limit was 0.03 mg/l, and samples without detectable hsCRP were assigned this 
value. Serum was stored at -80°C and hsCRP levels were measured approximately 2 
years after the serum was collected. The analysis was performed at an accredited, 
biomedical laboratory using their standard assay for CRP analysis, the CRP (Latex) US 
(Hoffman- La Roche, Switzerland). The assay provider (Hitachi/Roche) has tested 
reproducibility both within run (% coefficient of variation, CV, 0.43-1.34) and between 
days (% CV 2.51-5.70) as well as method comparison (r =0.996). The tested sample 
concentrations were between 0.11 and 18.63mg/l. The age and sex distribution of 
hsCRP values in our studies were largely comparable to those of other large population-
based studies from Europe.162 
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2.3 Statistical analyses 
All statistical analyses were conducted with STATA 10.1 for windows (Stata Corp.). 
 
2.3.1 Prospective analyses (papers I and II) 
In papers I and II, we used Cox proportional hazard models to examine the association 
of insomnia symptoms with subsequent risk of AMI and heart failure, respectively. We 
calculated hazard ratios (HRs) with 95% confidence intervals (CIs). We assessed the 
influence of each insomnia symptom using the original 4 response categories. Each 
category of reported insomnia symptoms was compared with reporting no insomnia 
complaints. For tests of trend, we assigned a numeric value of 0 to 3 to the insomnia 
categories, with 0 having no insomnia complaints, treating the categories as a 
continuous variable.  
Insomnia symptoms were also dichotomized, and the highest categories, i.e., 
difficulty initiating sleep almost every night, difficulty maintaining sleep almost every 
night, and non-restorative sleep more than once a week, were compared with the rest of 
the categories. In a separate analysis, we calculated the risk associating with the 
increasing number of dichotomized insomnia symptoms when those without any 
symptom constituted the reference category.  
The associations of insomnia symptoms and risk for AMI were assessed in 
different multivariable models. We included age, sex, education, shift work, and marital 
status as potentially confounding factors in our models. Established cardiovascular risk 
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factors such as high blood pressure, low physical activity, high BMI, smoking, 
abstinence from alcohol and heavy drinking, dyslipidemia, diabetes mellitus and history 
of previous AMI (in paper II) may act as both confounding and mediating factors for the 
association of sleep disorders with cardiovascular risk. We therefore analyzed the data 
both with and without the factors included in the analyses. It is also not clear whether 
psychological distress is a cause or a consequence of sleep disorders. Thus, in separate 
analyses, we additionally adjusted for depression and anxiety.  
We also conducted several stratified analyses to examine whether the association 
of insomnia symptoms and cardiovascular diseases could be modified by other factors. 
We formally tested the homogeneity of stratum-specific relative risks. For these tests of 
interaction, we used the insomnia trend variables as defined above.  
In sensitivity analyses, we dealt with other possible confounders such as chronic 
somatic disorders and sleep medication/sedatives, either by adjusting for them in the 
analyses, or by restricting the study population. To address the possibility of reverse 
causation as an explanation for the observed associations, we excluded the first 5 years 
of follow-up and repeated the analyses. We also restricted the analyses to CVD cases 
that were confirmed at the hospital; thus, we excluded cases whose diagnosis was based 
on death certificates alone. In paper II, we also tested whether AMI during follow- up 
influenced our estimates of the association of insomnia and HF, and included AMI 
during follow-up as a time-dependent variable.  
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We tested the proportionality of hazards using log-log curves and formal tests of 
interaction with time or log-time. There was no evidence against the proportionality 
assumption (P>0.10). 
 
2.3.2 Cross- sectional analyses (paper III and IV) 
The HsCRP levels were log-transformed due to skewed distribution. The association of 
hsCRP levels with insomnia symptoms (paper III) and metabolic factors (paper IV) 
were assessed in different multivariable models using linear regression with hsCRP as 
the dependent variable. The multivariable models included potential confounders. The 
inclusion of these potentially confounding covariates was based on prior knowledge. To 
address the robustness of our findings, hsCRP was also analyzed after categorization. 
Analyses were conducted separately for men and women, based on previous studies 
suggesting sex differences. 
 
2.3.2.1 Insomnia and hsCRP (paper III) 
The association of insomnia symptoms with hsCRP levels was assessed in four different 
models. In model 1, we adjusted for age only. In model 2, we adjusted for age, 
education, marital status, shift-work, smoking, alcohol, physical activity, blood 
pressure, BMI, diabetes mellitus, serum lipids, and hormonal status for women. Model 3 
was identical to model 2, with additional adjustment for depression and anxiety 
45 
 
symptoms and chronic pain. Model 4 was the same as model 3, but the analyses were 
restricted to participants without a history of chronic disease.  
We calculated standardized and unstandardized regression coefficients with 95% 
confidence intervals for each category of insomnia symptoms, using people with no 
insomnia complaint as the reference. For tests of linear trend, we assigned a numeric 
value of 0 to 3 to the insomnia categories, with 0 having no insomnia complaints, 
treating the categories as a continuous variable. In separate analyses, a quadratic term 
was included to assess non-linear trends. We also calculated the regression coefficients 
associated with the cumulative number of dichotomized insomnia symptoms using 
those without any symptoms as the reference category.  
Multiple imputations were performed on participants selected for hsCRP 
measurement but who did not respond to questions concerning insomnia or who had 
missing covariate information. Imputation was performed using the ICE-solution in 
Stata and 20 imputed datasets were created to achieve maximum accuracy. All the 
variables in the analyses, including the dependent variable, were used to impute missing 
values, as well as other HUNT variables not included in the present analysis. In 
addition, we also performed complete case analyses.  
 
2.3.2.2 Metabolic factors and hsCRP (paper IV) 
The associations of each metabolic factor (BMI, mean systolic and diastolic blood 
pressure, HDL cholesterol, non-HDL cholesterol, and triglycerides) with mean hsCRP 
were assessed in three different models: (1) adjusted for age; (2) adjusted for non-
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metabolic confounders (age, smoking, alcohol, and, in females; estrogen hormone 
replacement therapy, oral contraception, or ongoing pregnancy); and (3) with additional 
adjustment for the other metabolic factors. We estimated the adjusted and unadjusted 
percentage difference in hsCRP (with 95% confidence interval) per one standard 
deviation (SD) difference in each metabolic factor. In stratified analyses, we analyzed 
younger (20-34 years), middle-aged (35-59 years), and older (60 years and above) 
participants separately.  
In a separate analysis, the participants were placed in three categories of 
metabolic risk factors. We defined the following cut-off points to indicate increased 
metabolic risk: waist circumference ≥ 94 cm for men and ≥ 80cm for women, serum 
triglycerides ≥ 1.7 mmol/l, HDL < 1.0 mmol/l for men and < 1.3 mmol/l for women, 
systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, and 
prevalent diabetes mellitus. Participants without any unfavorable level of metabolic 
factors were classified as low risk, those with unfavorable levels of one or two 
metabolic factors were classified as intermediate risk, and those with three of more 
metabolic factors with unfavorable values were classified as high risk individuals. We 
estimated geometric mean hsCRP within each 10-years age group for each of these 
metabolic groups and assessed whether hsCRP differed between the groups. Linear 
regression modeling was also applied to test differences across metabolic risk categories 
for hsCRP in different age groups.
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3 Results 
3.1 Paper I: Insomnia and the risk of acute myocardial infarction: A 
population study 
We assessed insomnia symptoms and risk of acute myocardial infarction in 52,610 
participants with no history of previous AMI and answering one or more of the 
questions related to insomnia. Prevalences of having difficulties maintaining sleep 
almost every night, having difficulties maintain sleep almost every night and having 
non-restorative sleep more than once a week were 3.3 %, 2.5 %, and 8.0 %, 
respectively.   
Table 4 displays characteristics of the study population according to difficulties 
initiating sleep. High frequency of insomnia symptoms was most prevalent among older 
participants and was more frequent among women than men. In general, insomnia 
symptoms were associated with cardiovascular risk factor in a dose-dependent manner. 
There was also a strong association between insomnia symptoms and depression, 
anxiety, and the use of sleep medication/sedatives. The other two insomnia symptoms, 
difficulty maintaining sleep and feeling of non-restorative sleep, showed largely similar 
associations to these characteristics. 
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Table 4. Baseline characteristics of the HUNT-2 participants, free of history of AMI at baseline, 
according to difficulties initiating sleep (Paper I) 
  Never Sometimes Often Almost every night 
Variable N % (n) % (n) % (n) % (n) 
Total  51,982 55.1 (28,630) 36.2 (18,818) 5.5 (2,846) 3.3 (1,691) 
Sex (male) 23,226 48.3 (14,008) 41.2 (7,754) 33.0 (939)  31.0 (525) 
Diabetes mellitus   1,411   2.4 (690)   2.8 (522)   3.4 (95)   6.2 (104) 
Current smoking 14,611 25.1 (7,145) 30.5 (5,718) 39.9 (1,130) 36.7 (618) 
Physical inactive 18,109 36.0 (9,439) 36.0 (6,738) 46.4 (1,167) 55.8 (765) 
Shift work*  7,673 21.2 (4,249) 23.8 (2,847) 25.5 (433) 22.4 (144) 
Living alone 20,154 37.8 (10,806) 39.6 (7,421) 40.9 (1,162) 45.3 (765) 
Education <=9 years 17,546 31.6 (8,707) 37.5 (6,740) 44.7 (1,205) 58.5 (894) 
Use of sleep medicine/sedatives daily  2,021  1.4 (348)   4.2 (711) 11.5 (299) 42.9 (663) 
 N Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age (years) 51,982   47.7 (16.6)   50.8 (16.8)  52.1 (16.4)   59.4 (18.1) 
BMI (kg/m2) 51,682   26.3 (4.0)   26.4 (4.1)  26.5 (4.4)   26.6 (4.3) 
Systolic BP (mmHg) 51,822 136.8 (21.2) 138.1 (21.9) 138.0 (22.1) 142.6 (24.6) 
Diastolic BP (mmHg) 51,822   79.9 (12.0)   80.5 (12.2)   80.8 (12.0)   81.5 (12.7) 
Total cholesterol (mmol/L) 51,884    5.8 (1.2)     6.0 (1.3)    6.1 (1.3)    6.3 (1.3) 
HDL cholesterol (mmol/L) 51,871    1.4 (0.4)     1.4 (0.4)    1.4 (0.4)    1.4 (0.4) 
Triglycerides (mmol/L) 51,884    1.7 (1.1)     1.8 (1.1)    1.8 (1.2)    2.0 (1.2) 
Depressive symptoms 50,554    2.8 (2.7)     3.9 (3.1)    5.3 (3.7)    6.0 (4.0) 
Anxiety symptoms 49,827    3.4 (2.8)     4.9 (3.3)    6.9 (4.1)    7.3 (4.5) 
* Those who answered yes to the question: “Do you have shift work, night work or standing by duties?” 
 
During 11.4 years of follow-up a total of 2,368 participants had a first AMI. A 
total of 1,813 were diagnosed at hospital admission and 555 cases were identified based 
on information from the National Cause of Death Registry.  
Table 5 presents the multivariable adjusted hazard ratios for AMI in relation to 
insomnia symptoms. Having difficulty initiating sleep, difficulty maintaining sleep, and 
having the feeling of non-restorative sleep were associated with a moderately increased 
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risk of AMI compared with those who reported never or almost never to have these 
symptoms. After adjustment for established cardiovascular risk factors, the effect sizes 
of the associations were attenuated slightly, however, the estimates of effect were not 
further attenuated after additional adjustment for depression or anxiety, respectively. 
Among the insomnia symptoms, difficulties initiating sleep appeared to have the 
strongest and most robust association with AMI.  
As shown in Table 6, when we combined the insomnia symptoms, a dose-
dependent association was seen between the number of insomnia symptoms and AMI 
risk.  
Furthermore, we performed stratified analyses in subgroups to ensure that our 
results were consistent. When compared with men, women appeared to have somewhat 
higher relative risks of AMI associated with difficulties initiating sleep almost every 
night and cumulative insomnia symptoms (P for homogeneity 0.009 and 0.015, 
respectively). We found no statistical evidence for any effect modification by other 
stratifying factors, i.e., age, BMI, cholesterol, education, shift work, blood pressure, 
smoking status, and the association of insomnia with AMI risk was largely consistent in 
these subgroup analyses. 
 
 
 
  
Table 5. Hazard ratios for AMI according to insomnia symptoms (paper I) 
 
                                             Events/  Model 1 Model 2 Model 3 Model 4 Model 5 
Variable Person time 95 % CI 95 % CI 95 % CI 95 % CI 95 % CI 
Difficulty initiating sleep       
Never  1166/ 324352 Ref. Ref. Ref. Ref. Ref. 
Occasionally   840/ 210079   1.01 (0.92-1.10)  1.04 (0.94-1.14)  1.02 (0.91-1.13)  1.02 (0.92-1.14) 1.04 (0.93-1.16) 
Often 140/ 31300   1.19 (1.00-1.42)  1.18 (0.97-1.43)  0.98 (0.78-1.22)  0.98 (0.78-1.24) 1.06 (0.84-1.34) 
Almost every night 162/ 17059   1.58 (1.34-1.87)  1.53 (1.27-1.84)  1.45 (1.18-1.80) 1.48 (1.18-1.84) 1.53 (1.21-1.92) 
P for trend  <0.0001 <0.0001 0.019 0.018 0.005 
       
Difficulty maintaining sleep       
Never 718/ 283601 Ref. Ref. Ref. Ref. Ref. 
Occasionally 1265/ 247383   1.06 (0.96- 1.16)  1.02 (0.92- 1.13)  1.06 (0.95-1.18) 1.06 (0.95-1.19) 1.10 (0.98-1.23) 
Often 228/ 39960   1.11 (0.96- 1.30)  1.08 (0.92- 1.26)  1.10 (0.91-1.32) 1.15 (0.95-1.39) 1.22 (1.01-1.48) 
Almost every night 116/ 13110   1.39 (1.14- 1.70)  1.33 (1.07- 1.65)  1.30 (1.01-1.68) 1.32 (1.01-1.72) 1.46 (1.11-1.90) 
P for trend  0.003 0.033 0.049 0.025 0.002 
       
Feeling of non-restorative sleep       
Never, few times a year   742/ 350581 Ref. Ref. Ref. Ref. Ref. 
1-2 times per month 177/ 83777   0.94 (0.80- 1.10)   0.92 (0.77- 1.09)  0.91 (0.76-1.09) 0.91 (0.76-1.09) 0.95 (0.79-1.15) 
Once a week  97/ 35435   1.18 (0.96- 1.45)   1.18 (0.95- 1.46)  1.04 (0.82-1.33) 1.05 (0.82-1.34) 1.15 (0.90-1.47) 
More than once a week 133/ 39801   1.30 (1.08- 1.57)  1.32 (1.09-1.60)  1.27 (1.03-1.57) 1.25 (1.00-1.55) 1.41 (1.13-1.76) 
P for trend  0.007 0.006 0.074 0.115 0.006 
 
For models, see Table 6. 
  
Table 6. Hazard ratios for AMI according to the number of insomnia symptoms (paper I) 
 
                                                                                                                 
  Model 1 Model 2 Model 3 Model 4 Model 5 
Number of symptoms Events / person time  HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI 
0 997/ 463131 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
1 212/ 37710 1.24 1.00- 1.54 1.28 1.03-1.59 1.19 0.94-1.50 1.19 0.94-1.51 1.30 1.02-1.65 
2 81/ 12727 1.47 1.07-2.02 1.44 1.04-2.00 1.39 0.98-1.97 1.34 0.94-1.93 1.47 1.02-2.13 
3 13/ 2417 1.92 1.11-3.33 1.73 0.98-3.06 1.89 1.04-3.44 1.73 0.92-3.25 2.12 1.13-4.00 
HR for each symptom increase  1.24 1.11-1.38 1.22 1.10-1.37 1.20 1.06-1.35 1.18 1.04-1.34 1.25 1.08-1.45 
P for trend   <0.0001  <0.001  0.003  0.011  0.001 
 
Model 1: adjusted for age and sex.  
Model 2: model 1 + marital status, education, and shift-work.  
Model 3: model 2 + systolic blood pressure, total cholesterol, diabetes mellitus, BMI, physical activity and smoking.  
Model 4: model 3 + depression.  
Model 5: model 3 + anxiety. 
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Several sensitivity analyses were conducted to assess the robustness of our 
findings. The results did not materially change by excluding the first 5 years of follow-
up, by restricting outcomes to hospital-verified AMI, or excluding users of sleep 
medication/sedatives. In another sensitivity analyses, we excluded participants with 
known chronic disorders. The association of insomnia with AMI risk among these 
individuals was similar to that observed in the entire cohort.  
 
3.2 Paper II: Insomnia and risk of incident heart failure: A 
population study 
We assessed the prospective association of insomnia symptoms with the risk of incident 
heart failure in 54,279 men and women who were free of known heart failure at baseline 
and who answered one or more of the questions related to insomnia.  
Table 7 displays characteristics of the study population according to the 
cumulative number of insomnia symptoms. Older participants were more likely to have 
insomnia symptoms and symptoms were more frequent in women than men. In general, 
insomnia symptoms were associated with cardiovascular risk factors in a dose-
dependent manner. There was also a strong association between insomnia symptoms 
and depression, anxiety, and the use of sleep medication/sedatives.  
A total of 1,489 cases of heart failure occurred during 11.3 years of follow-up, 
1,004 cases were diagnosed at hospital admission, and 408 cases were identified based 
on information from the National Cause of Death Registry.  
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Individual insomnia symptoms were associated with increased risk of incident 
HF in our models adjusted for age, sex, education, shift-work, and marital status. After 
further adjustment for established cardiovascular risk factors, and previous AMI, the 
strength of the associations was attenuated. The multiadjusted hazard ratios for HF in 
Model 3 were 1.32 (95% CI 1.01-1.72) for people with difficulties initiating sleep 
almost every night, 1.26 (CI 0.93-1.72) for those with difficulties maintaining sleep 
almost every night, and 1.08 (CI 0.72-1.61) for those with a feeling of non-restorative 
sleep more than once a week compared with people who never experienced these sleep 
problems. The estimates of effect were further attenuated after adjustment for 
depression and anxiety. 
As shown in Table 8, the cumulative number of insomnia symptoms was 
associated with increased risk of HF in a dose-dependent manner in all models.  
We conducted several stratified analyses to assess whether the associations of 
insomnia symptoms and HF could be modified by other factors. Compared to men, 
women appeared to have a higher relative risk of HF associated with non-restorative 
sleep and with the cumulative symptoms of insomnia (P for homogeneity of HR 0.004 
and 0.016, respectively). In other stratified analyses we found no statistical evidence for 
effect modification. 
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Table 7. Baseline characteristics of the HUNT-2 participants free of HF at baseline according to 
cumulative number of insomnia symptoms (paper II) 
 
Number of insomnia symptoms  0 1 2 3 
Variable N % (n) % (n) % (n) % (n) 
Total  44,047 91.1 (40,134) 2.7 (2,711) 2.2 (978) 0.5 (224) 
Sex (male) 20,205 47.0 (18,870) 34.2 (926) 34.8 (340) 29.9 (67) 
Diabetes mellitus      770   1.7 (666)   2.4 (66)   3.1 (30)   3.6 (8) 
Current smoking 13,423 29.6 (11,858) 38.4 (1,037) 45.2 (440) 39.6 (88) 
Physical inactive 15,140 35.2 (13,456) 46.6 (1,145) 49.3 (436) 52.6 (103) 
Shift work*   7,685 22.3 (7,108) 22.9 (420) 20.9 (129) 21.7 (28) 
Living alone 16,496 37.7 (15,108) 34.8 (941) 36.8 (359) 39.3 (88) 
Education <=9 years 12,703 27.7 (10,905) 47.1 (1,230) 48.2 (455) 52,8 (113) 
Use of sleep medicine/sedatives daily   1,235   1.8 (663) 10.8 (269) 24.4 (221) 39.0 (80) 
Previous myocardial infarction      709   1.5 (609)   2.2 (60)   3.3 (32)   3.6 (8) 
 N Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age (years) 44,047   44.1 (13.2)   49.5 (12.5)   50.1 (13.2)   53.0 (12.0) 
BMI (kg/m2) 43,916   26.1 (4.0)   26.7 (4.6)   26.8 (4.6)   26.5 (4.6) 
Systolic BP (mmHg) 43,922 133.5 (18.7) 135.9 (19.7) 134.2 (19.7) 136.9 (20.7) 
Diastolic BP (mmHg) 43,922   79.1 (11.6)   80.9 (11.6) 79.9 (11.7) 81.9 (11.3) 
Total cholesterol (mmol/L) 43,966     5.7 (1.2)     6.1 (1.3)   6.1 (1.3)   6.3 (1.4) 
HDL cholesterol (mmol/L) 43,954     1.4 (0.4)     1.4 (0.4)   1.4 (0.4)   1.4 (0.4) 
Triglycerides (mmol/L) 43,966     1.7 (1.1)     1.8 (1.2)   1.9 (1.3)   2.0 (1.2) 
Depressive symptom score 43,513     3.1 (2.8)     5.1 (3.7)   6.1 (3.9)   7.0 (4.3) 
Anxiety symptom score 43,286     4.1 (3.1)     6.6 (4.0)   7.7 (4.3)   9.0 (4.8) 
* Those who answered yes to the question: “Do you have shift work, night work or standing by duties?” 
 
 
 Table 8. HRs and 95% CIs for heart failure according to cumulative number of insomnia symptoms (paper II) 
 
 
  Model 1 Model 2 Model 3 Model 4 Model 5 
Number of symptoms Events / person time  HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI 
0 270/471292 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
1 28/31515 1.17 0.79-1.73 1.20 0.80-1.80 0.96 0.57-1.61 0.91 0.59-1.52 0.95  0.55-1.62 
2 18/11037 1.92 1.19-3.11 1.88 1.13-3.13 1.35 0.72-2.50 1.20 0.64-2.26 1.43 0.76-2.69 
3 7/2490 2.95 1.39-6.27 2.69 1.19-6.08 4.53 1.99-10.31 3.83 1.66-8.85 5.25 2.25-12.22 
HR for each symptom increase  1.37 1.15-1.62 1.35 1.12-1.62 1.29 1.04-1.61 1.23 0.98-1.54 1.34 1.06-1.68 
P for trend   <0.001  0.001  0.021  0.077  0.013 
 
Model 1, adjusted for age and sex 
Model 2, Model 1 + marital status, education, and shift-work 
Model 3, Model 2 + systolic blood pressure, total cholesterol, diabetes mellitus, BMI, physical activity, smoking, alcohol and previous AMI. 
Model 4, Model 3 + depression 
Model 5, Model 3 + anxiety 
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Several sensitivity analyses were performed, and the results did not materially 
change by excluding the first five years of follow-up, restricting follow-up to HF cases 
that were confirmed at the hospital, or adjusting for use of sleep medication/sedative. 
Adjustment for chronic diseases only slightly attenuated the association of insomnia 
with HF risk compared to the results of the main analyses. No appreciable change in our 
estimates occurred after adjustment for incident AMI as a time-dependent covariate 
during follow-up. 
 
3.3 Paper III: Insomnia and high-sensitivity C-reactive protein: The 
HUNT study, Norway 
A total of 8,547 men and non-pregnant women answered one or more of questions 
related to insomnia out of 9,995 participants with available hsCRP measurement in the 
HUNT study.  
Among men, using multivariable linear regression analyses of the logarithm of 
hsCRP, difficulties initiating sleep and non-restorative sleep were associated with 
increasing hsCRP levels after adjustment for age. However, after additional adjustment 
for cardiovascular risk factors the associations were attenuated. In men, HsCRP was not 
associated with having difficulties maintaining sleep, insomnia with influence on work 
or with the cumulative number of insomnia symptoms (Table 9). 
 Table 9. Regression coefficients with 95% confidence interval for the association of hsCRP and cumulative number of insomnia symptoms (multiple imputation) 
(paper III) 
 
 Model 1  Model 2  Model 3  Model 4 
Variable B* 95% CI β**  B* 95% CI  β**  B* 95% CI β**  B* 95% CI β** 
For women                 
0 Ref  Ref  Ref  Ref  Ref  Ref  Ref  Ref 
1 0.02 -0.14 to 0.18  0.01  0.01 -0.14 to 0.15  0.00  0.01 -0.14 to 0.16  0.01  0.00 -0.19 to 0.20  0.00 
2 -0.05 -0.23 to 0.13 -0.03  -0.09 -0.25 to 0.08 -0.06  -0.08 -0.25 to 0.09 -0.05  -0.04 -0.28 to 0.20 -0.02 
3 0.07 -0.23 to 0.13  0.04  -0.03 -0.25 to 0.19 -0.02  -0.01 -0.24 to 0.22 -0.01  -0.25 -0.59 to 0.08 -0.16 
                
Linear trend 0.00 -0.06 to 0.06   -0.02 -0.08 to 0.03   -0.02 -0.08 to 0.04   -0.05 -0.13 to 0.04  
P for trend 0.92    0.46    0.60    0.27   
P for quadratic trend 0.72    0.93    0.90    0.33   
n 4,378    4,378    4,378    2,977   
                
For men                 
0 Ref  Ref  Ref  Ref  Ref  Ref  Ref  Ref 
1 0.20 0.02 to 0.36 0.13  0.13  -0.03 to 0.30 0.09  0.15   -0.02 to 0.32  0.10  0.14 -0.06 to 0.34 0.09 
2 0.09 -0.13 to 0.32 0.06  0.03  -0.19 to 0.25 0.02  0.06  -0.17 to 0.29 0.04  0.03 -0.26 to 0.32 0.02 
3 0.10 -0.28 to 0.32 0.06  0.00  -0.37 to 0.37 0.00  0.04  -0.33 to 0.42 0.03  0.14 -0.37 to 0.66 0.09 
                
Linear trend 0.07 -0.01 to 0.15   0.03 -0.05 to 0.11   0.04 -0.04 to 0.13   0.05 -0.05 to 0.16  
P for trend 0.10    0.46    0.30    0.33   
P for quadratic trend 0.17    0.24    0.23    0.55   
n 3,901    3,901    3,901    2,969   
 
*Unstandardized beta coefficient 
** Standardized beta coefficient 
Model 1 age adjusted; Model 2 adjusted for age, marital status, education, shift-work, systolic– and diastolic blood pressure, triglycerides, HDL- and total cholesterol, diabetes mellitus, BMI, physical 
activity, smoking and alcohol intake, and hormonal status in women; Model 3 adjusted for the same variables as in model 2 and depression score, anxiety score and chronic pain; Model 4 adjusted for the 
same variables as in model 3, but restricted to those without a chronic somatic disorder.
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In women, there was no evidence for an association of individual insomnia 
symptoms with hsCRP levels.  
The associations of insomnia and hsCRP were largely the same in the complete 
case analyses as those obtained performing multiple imputations.  
 
3.4 Paper IV: Metabolic factors and high-sensitivity C-reactive 
protein: the HUNT study 
A total of 4,503 men and 4,411 women without missing data on hsCRP and metabolic 
factors were included in our analyses.  
In the multivariable analyses, all the metabolic factors were significantly 
associated with hsCRP, with the exception of systolic blood pressure in women and 
non-HDL cholesterol in men (Table 10A and B). Among the metabolic risk factors, 
BMI appeared to be the most strongly associated factor, and showed a strong positive 
association with hsCRP also after adjustment for the other metabolic factors, with 
similar associations in women and men. HsCRP was 37.6% higher per standard 
deviation increase in BMI for men and 48% higher for women after multivariable 
analyses. Stratifying the analysis according to age groups showed that the associations 
between metabolic factors and hsCRP were fairly robust. The associations were 
generally slightly stronger in younger than in older age groups. In the youngest age 
group, hsCRP was 54.3% higher per standard deviation increase in BMI for men and 
62% higher for women after multivariable adjustment, and the corresponding 
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differences were 39.3% and 57.8% in the middle aged group, and 28.9% and 28.0% in 
the oldest age group.  
In a secondary analysis, using hsCRP in categories the results were essentially 
similar to those of the primary analysis.  
 
 
 
Table 10A. Percentage difference in mean hsCRP per standard deviation difference with a 95% 
confidence interval in each metabolic risk factor among females (n=4381) estimated in linear 
regression (paper IV) 
 
 
Metabolic risk factor Model 1 Model 2 Model 3 
Body mass indexª     
per S.D. (=4.1) 57.0 (50.8 to 63.4) 59.0 (53.0 to 65.4) 48.0 (41.9 to 54.5) 
Mean systolic BPⁿ    
per S.D. (=21.9) 23.4 (17.0 to 30.2) 22.3 (15.4 to 28.8) -0.1 (-6.9 to 7.1) 
Mean diastolic BPⁿ    
per S.D. (=12.2)            22.1 (16.4 to 28.2) 22.0 (16.4 to 28.0) 10.0 (3.0 to 17.2) 
Triglycerides    
per S.D. (=1.12)            47.7 (39.8 to 56.0) 42.5 (34.9 to 50.4) 10.7 (3.9 to 18.2) 
HDL cholesterol    
per S.D. (=0.39)           -24.2 (-27.5 to -20.7) -24.8 (-28.0 to -21.5) -13.6 (-17.6 to -9.4) 
Non HDL cholesterol    
per S.D. (=1.26)              16.2 (10.5 to 22.1) 14.0 (8.5 to 19.8) -6.5 (-11.2 to -1.5) 
 
 
Values are percentage in mean hsCRP per standard deviation difference (95% confidence interval). The percentage change is on the 
linear scale. a: n =4353. n: n=4379. In addition to previous exclusions, 28 and 2 women with missing information on BMI and blood 
pressure measurements respectively were excluded from this part of the analysis.  
Model 1, adjusted for age; Model 2, adjusted for age, smoking, alcohol intake, estrogen hormone replacement therapy, oral 
contraception or ongoing pregnancy; Model 3, model 2 + the other metabolic risk factors.
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Table 10B.  Percentage difference in mean hsCRP per standard deviation difference with a 95% 
confidence interval in each metabolic risk factor among males (n=4491) estimated in linear 
regression (paper IV) 
 
 
Metabolic risk factor     Model 1       Model 2           Model 3 
Body mass indexª     
per S.D. (=4.1)   41.1 (34.2 to 48.1)   45.5 (38.5 to 52.8)        37.6 (30.5 to 45.1) 
Mean systolic BPⁿ    
per S.D. (=21.9)     5.2 (1.00 to 11.2)     6.1 (0.5 to 12.0)         -9.7 (-16.1 to -2.7) 
Mean diastolic BPⁿ    
per S.D. (=12.2)              12.3 (6.9 to 17.8)   13.2 (7.9 to 18.8)        13.5 (6.2 to 21.3) 
Triglycerides    
per S.D. (=1.12)              10.0 (6.0 to 14.2)     9.5 (5.5 to 13.7)        -5.2 (-9.1 to -1.0) 
HDL cholesterol    
per S.D. (=0.39)            -23.0 (-26.7 to -19.3)  -23.2 (-26.8 to -19.3)      -17.2 (-21.4 to -12.7) 
Non HDL cholesterol    
per S.D. (=1.26)                13.0 (7.6 to 18.6)   12.7 (7.4 to 18.3)         2.3 (-2.9 to 7.9) 
 
Values are percentage difference in mean hsCRP per standard deviation difference (95% confidence interval). The percentage 
change is on the linear scale. a: n=4482. n: n=4488. In addition to previous exclusions 9 and 3 men with missing information on 
BMI and blood pressure measurements respectively were excluded from this part of the analysis. Model 1, adjusted for age; 
Model 2, adjusted for age, smoking, and alcohol intake; Model 3, model 2 + the other metabolic risk factors 
 
 
 
In a separate analysis, we placed the participants in three categories of metabolic 
risk factors within each 10-years age group (Figure 4A and B). We found statistical 
evidence for an association between hsCRP and metabolic risk across all age groups in 
both genders. Participants with high metabolic risk had consistently higher hsCRP 
values compared to the rest of the population and hsCRP appeared to be higher in the 
intermediate metabolic group compared to the low-risk group. 
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Figure 4A. Distribution of hsCRP among women according to metabolic risk (paper IV) 
 
 
 
Figure 4B. Distribution of hsCRP among men according to metabolic risk (paper IV) 
 
*Total number of participants in each age group; ** p value for test of homogeneity of the hsCRP values across three 
categories of metabolic risk (linear regression). 
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4 Discussion 
Our overall aim was to investigate the prospective associations of insomnia with risk for 
AMI and HF, and to explore possible mechanisms behind these associations. Briefly, 
our principal findings can be summarized as follows: 
- Insomnia was associated with a moderately increased risk for AMI. 
- Insomnia was associated with an increased risk of incident heart failure. 
- There were no consistent associations between insomnia symptoms and hsCRP 
levels.  
- Metabolic factors, especially body mass index, had a relatively strong 
association with hsCRP at all ages both in men and women. 
 
4.1. Strengths and Limitations 
Below we discuss the methodological strengths and limitations of this thesis. We 
systematically review the typical sources of error in epidemiology, i.e. the difference 
between the observed and the causal effect, and discuss the possibilities of these errors 
in our studies.  
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4.1.1 Random error 
The observed associations in epidemiological studies may always be influenced by 
chance or unexplained variability in the data. Random error can be defined as 
fluctuation in the data caused by any factors that randomly affect the result of the 
measurement.163 Analogously, the opposite of random error is precision, and an 
estimate with little random error is described as precise. In our study, we indicated the 
precision of the estimates by 95% confidence intervals.  
We had an ample sample size compared to most previous studies and therefore, 
the estimates generally showed high precision, with relatively narrow confidence 
intervals. The large sample size also made these studies relatively well powered to 
detect subgroup differences. 
 
4.1.2 Systematic error (lack of internal validity) 
Systematic error, often referred to as bias, is the other main type of error in 
epidemiology. The opposite of bias is validity, and an estimate with little systematic 
error is considered to be valid. Systematic error can be defined as any process or effect 
that leads to nonrandom deviation of results from the true, i.e. causal values. In contrast 
to random error that is decreasing with increasing size of the study, systematic error 
does not depend on sample size.163 Most violations of the internal validity of a study can 
be classified in three categories; confounding, selection bias, and information bias. 
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4.1.2.1 Confounding 
Confounding can be thought of as a mixture of the effect of the exposure with effects of 
other factors. Confounding can lead to overestimation, underestimation, and even to a 
change in the direction of the estimated effect of interest.164 The clearest form of 
confounding is seen when the factor is a common cause for both the exposure and the 
outcome. A factor must fulfill at least two criteria to be regarded as a confounding 
factor. Firstly, a confounder must be related to the exposure under study, but it must not 
be affected by the exposure. Secondly, a confounder must be related to the outcome, but 
not be affected by it. Although both these criteria are necessary, they are not 
sufficient.163  
It is important to note that a factor that is associated with both the exposure and 
the outcome may be mediating the effect of the exposure, and therefore, it is on the 
causal pathway between the exposure and the outcome, and such mediating factors 
should not be regarded as confounders. In the assessment of which factors should be 
regarded as potential confounders, the basis should be prior knowledge about their 
relations with the exposure and the outcome; in other words, the inclusion of 
confounders in the analysis should not be assessed on statistical grounds only.164  
The HUNT2 study had comprehensive clinical, demographic and psychosocial 
data on each participant, and therefore, we could control for many confounding factors 
in the statistical analyses. However, we cannot exclude the possibility of uncontrolled 
confounding, i.e. that factors for which we had no information could have a 
confounding effect. Nevertheless, any remaining confounder potentially able to 
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influence our results considerably would need to be strongly associated with both the 
exposure and the outcome, and be unrelated to the other factors that were included in 
the analysis.  
For example, we had no information on the prevalence of sleep apnea syndrome, 
which is a possible confounder for the association of insomnia with CVD, since sleep 
apnea syndrome is a well-established risk factor for cardiovascular disorders.6 Also, 
apnea patients often complain about difficulties in initiating or maintaining sleep, and 
they often suffer from early awakenings.165 However, the strength of the association 
between sleep apnea and insomnia is not clear, and it has been suggested that the 
association could be explained, at least in part, by confounding by age and 
depression.165,166 In the analyses, we adjusted for age and depression, as well as for 
blood pressure and BMI, i.e., for strong correlates of sleep apnea syndrome and CVD. 
Therefore, it appears unlikely that sleep apnea alone could explain the higher risk for 
AMI and HF among people with insomnia symptoms. 
 
4.1.2.2 Selection bias 
Selection bias is a distortion that results from erroneous selection of the participants in 
the study.163,167 The common element of such biases is that the relation of the exposure 
to the outcome is different for those who participate and those who theoretically would 
be eligible for the study.  
 The participation rate in the HUNT study was generally higher than in most 
other large population studies. However, 31 % of those who were invited did not 
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participate in HUNT 2. The participation rate among participants 20 to 25 years of age 
was considerably lower than among older age groups. Therefore, caution is needed, for 
example, when interpreting our finding concerning the association of metabolic factors 
and hsCRP among the youngest age group in paper IV. However, a comprehensive non-
participation study was conducted after HUNT 2, and the major reason for not 
participating among younger people was the lack of time.156 Therefore, there is no 
reason to believe that a health-related selection mechanism is the reason for the lower 
participation among the youngest age groups.  
 Biased follow-up could potentially distort the results of prospective studies, and 
potentially lead to selection bias (paper I and II). Data on emigration provided by 
Statistics Norway enabled us to censor participants who moved away from Nord-
Trøndelag, however, the population is stable with a low net migration out of the 
county.156 Loss to follow-up, which is often a major problem in prospective cohort 
studies of the general population,163 is therefore unlikely to play an important role in our 
studies. 
   
4.1.2.3 Information bias 
Information bias occurs whenever the collected information on the participants is 
erroneous. Such misclassification, either related to exposure or to outcome, can be 
differential or non-differential. Misclassification of exposure is non-differential if it is 
unrelated to the outcome; and differential if the misclassification of exposure is 
dependent on the outcome. Similarly, misclassification of outcomes is non-differential 
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if unrelated to exposure; and otherwise, it is differential. Differential misclassification 
can either exaggerate or underestimate an effect. In contrast, non-differential 
misclassification typically tends to produce estimates of the effect that are closer to the 
null.163 
 Insomnia symptoms were self-reported and therefore subject to 
misclassification. Similar to other relevant studies, we did not assess sleep objectively, 
for example, by performing a polysomnography. However, polysomnography is not 
routinely used for evaluation of insomnia,168 because difficulty initiating sleep or 
maintaining sleep, or non-restorative sleep, cannot be objectively measured. In fact, 
insomnia may be present even in the absence of any sign of an objective sleep 
disturbance from a polysomnographic evaluation.168 Furthermore, we did not rely on a 
formal diagnosis of insomnia, and in the analyses, we assessed the severity of symptoms 
both separately, and in combination, in relation to the outcome of interest. However, our 
evaluation of insomnia symptoms largely reflected the current diagnostic criteria used in 
the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders.8 
 Prospective cohort studies are generally less prone to biased exposure 
ascertainment than other study designs. However, during long follow-up periods, 
measured values at baseline may change. Insomnia was evaluated only once at the 
beginning of the follow-up; thus, we could not examine the possible effects of time-
dependent changes in the severity of insomnia. However, lack of repeated 
measurements of insomnia cannot possibly explain the observed association of 
insomnia with the risk of later CVD.  
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The identification and ascertainment of AMI and HF as outcomes could also be 
prone to misclassification. However, the overall quality and reliability of the hospital 
discharge diagnosis of AMI and HF is high in Nordic countries.158,159 As there is no 
unequivocal definition of HF, the HF diagnosis in Nordic registers appears slightly less 
precise than for acute myocardial infarction. To further increase the specificity of the 
diagnosis we considered only primary diagnoses of HF, as recommended.158 The 
reliability of the diagnosis due to deaths of CVD from the Cause of Death Registry is 
somewhat lower than the reliability of hospital discharge diagnosis, largely because of 
the low autopsy rates in Norway.169 However, we obtained similar results by restricting 
follow-up to hospital confirmed cases of CVD; thus, it seems unlikely that low 
reliability of CVD deaths could explain the higher risk for CVD among people with 
insomnia symptoms.  
 The non-fasting nature of the blood samples could also introduce 
misclassification. Triglyceride concentrations are especially sensitive to eating whereas 
total serum cholesterol and HDL cholesterol levels may be less affected.170 In study IV, 
we hypothesized that applying stricter criteria, using fasting blood samples, would most 
likely result in even stronger associations between the respective metabolic factors and 
hsCRP.  
 
4.2 Generalizability (external validity) 
Generalizability refers to whether, and to which degree, our results apply to people 
outside of the population we studied. We see no relevant biological differences between 
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the adult population of Nord-Trøndelag and other adult populations that would make the 
effects of insomnia on CVD risk markedly different in other populations. However, the 
estimated effects of insomnia may vary between countries because of different latitudes, 
different underlying rates of AMI and HF and different sleeping/circadian habits in the 
populations. Moreover, the question related to non-restorative sleep in our studies was 
restricted to people younger than 70 years of age, and therefore, our results concerning 
this particular variable, and the cumulative number of insomnia symptoms, cannot 
readily and directly be generalized to elderly populations.   
 
4.3 Comparison with previous studies 
4.3.1 Insomnia and the risk of AMI 
In our study, insomnia symptoms were associated with a moderate increase in the risk 
for AMI. The results were fairly robust in different multivariable models and several 
sensitivity analyses. Although the observed relative risk of insomnia with AMI was only 
moderate, insomnia is a frequent, easily recognizable, and potentially manageable 
condition for most patients. The association of insomnia and AMI risk is in line with a 
few smaller studies which concentrated on difficulty in initiating and/or maintaining 
sleep.120-130  
Several studies have suggested that women are more prone to insomnia than 
men,9 and that there is a sex difference related to cardiovascular risk and mortality. In 
the MONICA study,122 the association of insomnia with CHD risk was stronger in 
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women, whereas the opposite was found by Mallon et al.121 Many previous studies were 
restricted to either men120,125,127,128 or women.126 In the present study, there was no 
compelling evidence for a sex difference. The relative risk of AMI associated with 
difficulties initiating sleep and for the cumulative insomnia symptoms was slightly 
higher in women than in men. However, the difference should be interpreted with 
caution; it does not necessarily suggest that insomnia is more dangerous for women. 
Instead, the sex difference might be explained by the lower baseline AMI risk among 
women.  
Prior reports of insomnia and CVD have been criticized for lack of adequate 
control for depression and anxiety, as well as for failing to include important 
confounders such as co-morbid chronic somatic disorders.  
In the present study, adjustment for depression did not substantially change the 
estimated associations. This corresponds to the findings of the few studies that could 
evaluate depressive symptoms in their analyses.121,122,124 Inclusion of anxiety in our 
models somewhat strengthened the association of insomnia complaints with AMI risk. 
This was an unexpected and unexplained result. To the best of our knowledge, no 
previous study included adjustment for anxiety, and future studies are warranted to 
confirm or refute our finding.  
Previously, one small study attempted to address the possibility that chronic 
disorders could explain the association between insomnia complaints and risk for 
AMI.121 Similar to our findings, there was no evidence in that study suggesting that 
chronic disorders could explain the observed association. We also addressed the 
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possibility of reverse causation as an explanation for the observed associations by 
excluding the first five years of follow-up, but this did not substantially change the 
results. Therefore, our study, together with most previous studies, seems to support a 
possible causal role for insomnia in the pathogenesis of CHD. 
 
4.3.2 Insomnia and the risk of HF 
We found that insomnia is associated with an increased risk of HF. To our knowledge, 
this is the largest study to date that has assessed insomnia in relation to the risk of HF.  
Previously, the association has been investigated in a few smaller studies.171,172 
In a recent prospective study by Ingelsson et al., 282 out of 2,314 middle-aged men 
were hospitalized with HF over 30 years of follow-up.171 Similar to our findings, they 
reported that difficulties initiating sleep were associated with a moderately increased 
risk of HF (HR 1.22, 95% CI 1.03-1.43), and difficulties maintaining sleep with a slight 
increase in risk of HF (HR 1.14, 95% CI 0.96-1.36). The investigators adjusted for 
several established risk factors for HF, including myocardial infarction during follow-
up, but they did not adjust for other somatic disorders or psychological distress. 
Newman et al. found that daytime sleepiness at baseline predicted incident HF and 
cardiovascular mortality in 5,888 participants above 65 years of age over a five year 
follow-up.172 However, the investigators did not adjust for several important established 
risk factors for HF.  
In contrast to previous studies, which assessed some selected insomnia 
symptoms, we included all aspects of sleep problems that are typically used to identify 
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insomnia.9 Therefore, we could also investigate the joint effect of insomnia symptoms. 
Similar to previous studies, we found a moderately increased risk related to individual 
symptoms, but among people with all three insomnia symptoms simultaneously; the risk 
was particularly high even after adjustment for established cardiovascular risk factors 
and psychological distress. Our finding may suggest that malfunctioning of some 
aspects of sleep may be somehow compensated, and the net effect on cardiovascular 
disease may be limited. For example, having difficulties falling asleep might be 
compensated by a satisfactory depth and a good continuity of sleep. However, if the 
initiation of sleep is poor and combined with repeated awakenings and superficial sleep, 
there may not be any compensatory mechanisms. 
 CHD is an important risk factor for HF. However, most HF cases are not 
preceded by a coronary event.173 In the analyses, we adjusted for a history of AMI at 
baseline and also for incident AMI during follow-up. These adjustments did not change 
the association of insomnia with incident HF. Moreover; when we analysed the joint 
effects of insomnia symptoms, the association of insomnia with incident HF was much 
stronger than for incident AMI. For example, having all three insomnia symptoms 
compared with none, was associated with more than three-fold higher risk (317% 
increased risk) of HF, as compared to less than two-fold higher risk (85% increase) of 
AMI  after adjustment for cardiovascular risk factors. Thus, it seems unlikely that the 
association between insomnia and HF observed in this study can be due to the 
association between insomnia and AMI.  
Although we found that insomnia is associated with increased risk of heart 
failure in our study, more population-based studies are needed to better establish the HF 
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risk associated with insomnia and to reveal the possible underlying pathophysiological 
mechanisms. 
 
4.3.3 Insomnia and hsCRP 
In this large population based study, we found no consistent associations between 
insomnia symptoms and hsCRP levels in either women or men after controlling for 
established cardiovascular risk factors, psychosocial distress, chronic pain, and after 
taking into consideration the role of chronic somatic disorders. 
 Women are more prone to insomnia,9 and in general, women have higher hsCRP 
levels than men.162,174 Moreover, both experimental studies on the effect of sleep 
deprivation on inflammatory markers,94 and studies examining the association of 
habitual insomnia and inflammation have suggested differences by sex.152,153 Therefore, 
it seems plausible that the association between insomnia and inflammation could also 
differ by sex, and we therefore conducted separate analyses for men and women. 
Among men, we found that difficulty initiating sleep and having non-restorative sleep 
were associated with higher hsCRP levels, but only in the age-adjusted models. Among 
women, we found no associations between insomnia symptoms and hsCRP levels.
 Several short-term experimental studies have demonstrated that acute sleep 
deprivation leads to increased levels of inflammatory markers, including hsCRP.94-99 
However, only a few studies have examined whether chronic sleep problems or habitual 
insomnia symptoms are associated with inflammation.152-155  
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 In a young Finnish birth cohort including 2,104 men and 1,907 women, there 
was a positive association between an aggregated sleep disturbance variable and hsCRP 
levels, but the association was restricted to men.153 The authors excluded participants 
with depression, but adjusted for several cardiovascular risk factors. In another study, 
difficulty initiating sleep and having non-restorative sleep were associated with a higher 
level of hsCRP and IL-6 among 95 healthy non-smoking women without any known 
chronic disorders.152 The analyses were adjusted for several cardiovascular risk factors 
and measures of psychological distress. Among the 115 men in the study, there was no 
association of sleep disturbances with hsCRP. In two other small studies, including 188 
and 43 individuals, difficulty initiating and maintaining sleep and non-restorative sleep 
were associated with higher hsCRP levels.154,155 However, in these studies there was no 
information on important cardiovascular risk factors.  
 As we found no strong evidence for any association between insomnia and 
hsCRP, further studies are needed to explore the possible pathophysiological 
mechanisms linking insomnia to the risk of CVD.  
   
4.3.4 Metabolic factors and hsCRP 
Insomnia appears to be associated with an unhealthy lifestyle and with the metabolic 
syndrome. However, the association of hsCRP and metabolic factors, especially in 
younger age groups, is not clear from the literature. In our study, we found that all the 
measured metabolic factors were relatively strongly associated with hsCRP at all ages 
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both in men and women. Among the metabolic factors, BMI displayed the strongest 
association. 
 To our knowledge, we have conducted the largest population-based study on this 
topic. Only a small number of previous studies have examined metabolic factors and 
hsCRP, and included both sexes in all age groups.175-177 Those studies were mainly 
conducted in middle-aged or older populations, and generally, it was reported relatively 
higher levels of hsCRP in individuals with metabolic syndrome in those studies. In the 
NHANES III, 8570 men and women older than 20 years of age were included, but 
specific findings on the association of metabolic syndrome with hsCRP in young 
participants were not reported.175 Another study assessed the association in young adults 
(24 to 43 years) and found that participants with metabolic syndrome had higher hsCRP 
levels.176 Similar to our study, the authors reported that BMI was the component of the 
metabolic syndrome that was most strongly associated with hsCRP. Similar findings 
among adolescents have also been reported.177 
 The associations between metabolic factors and hsCRP were slightly stronger in 
young people (20-34 years) than among older individuals. Other studies have shown 
strong correlations between the extent of atherosclerosis in adolescence and early 
adulthood and cardiovascular risk factors, including an adverse lipid profile, high blood 
pressure, and cigarette smoking, that are strongly predictive of the severity of 
atherosclerosis later in life.33,178,179 As atherosclerotic plaques at a young age are 
substantially less active than later in life, our findings may be regarded as indirect 
evidence against the hypothesis of reverse causality, i.e. the hypothesis that cytokines 
may leak from atherosclerotic plaques into the circulation with subsequent hepatic 
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synthesis of CRP (see Figure 1 on page 18). In contrast, it supports the hypothesis that 
metabolic factors may in themselves cause higher hsCRP. Thus, CRP may not only be a 
bystander in the relationship between the established risk factors and CVD. 
However, as our study is cross-sectional, the temporal relation between the 
development of the metabolic syndrome and hsCRP cannot be inferred. Therefore, the 
clinical usefulness of our findings in relation to coronary risk stratification of young 
adults remains to be addressed in prospective studies. 
 
5 Conclusion 
In this thesis we investigated the interrelations between insomnia, metabolic syndrome 
and inflammation, and the relation of these factors to the risk of CVD. Our findings are 
summarized in Figure 5.  
Our data support the potential importance of insomnia in the development of 
AMI and HF, two of the most common forms of CVD. Insomnia is a frequent, easily 
recognizable, and potentially manageable condition for most patients. However, 
especially the association of insomnia with increased risk of HF needs to be confirmed 
in other prospective population-based studies. Clinical trials are also needed to 
determine whether improving sleep may improve cardiovascular risk factor levels and 
outcomes. If our results are supported in other studies and causation is proved, 
evaluation of insomnia symptoms should be included in the clinical risk assessment and 
could be useful in cardiovascular prevention.  
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We tried to explore possible pathophysiological mechanisms behind the 
association of insomnia with CVD risk. We found no association of insomnia symptoms 
with hsCRP levels after controlling for established cardiovascular risk factors, 
psychosocial distress, chronic pain, and after taking into consideration the role of 
chronic somatic disorders. Therefore, our results do not support that inflammation, as 
reflected by elevated levels of hsCRP, is an important factor linking insomnia to CVD. 
It is largely established that insomnia is associated with an unhealthy lifestyle and with 
the metabolic syndrome. However, the association of hsCRP and metabolic factors is 
not clear from the literature. We found a relatively strong association of metabolic 
factors with hsCRP levels at all ages, and both in men and women. As atherosclerotic 
plaques at a young age are substantially less active than later in life, our findings may be 
regarded as indirect evidence against the reverse causation hypothesis, i.e. the increased 
hsCRP levels are only caused by active atherosclerotic plaques. Our results support the 
hypothesis that the metabolic factors in themselves may cause increased levels of 
hsCRP. Thus, CRP may not only be a bystander in the relationship between the 
established risk factors and CVD. Although our findings shed further light on the 
complex interrelation between insomnia and CVD, further studies are needed to 
disentangle the complex web of surrogates, correlates and causative factors.  
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Figure 5. Suggested interrelationships between insomnia, metabolic syndrome, inflammation, and cardiovascular 
disease. White arrows refer to associations proposed and investigated in this thesis. Black arrows indicate 
established relationships, which are not examined here.  
 
1. Insomnia might increase CVD risk: supported by our results. 
2. Insomnia and the metabolic syndrome are related: relatively well-established in 
previous studies, not investigated in this thesis. 
3. CVD causes insomnia: established in previous studies, not investigated in this thesis. 
4. Metabolic syndrome increases CVD risk: well-established, not investigated in this 
thesis. 
5. Inflammation increases CVD risk: well-established, not investigated here. 
6. The metabolic syndrome and inflammation are related: supported by our findings.   
7.    and 8. Inflammation and insomnia are related: not confirmed by our results.  
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